EYP-1901
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Nonproliferative Diabetic Retinopathy
Conditions
Nonproliferative Diabetic Retinopathy
Trial Timeline
Sep 28, 2022 → May 6, 2024
NCT ID
NCT05383209About EYP-1901
EYP-1901 is a phase 2 stage product being developed by EyePoint Pharmaceuticals for Nonproliferative Diabetic Retinopathy. The current trial status is completed. This product is registered under clinical trial identifier NCT05383209. Target conditions include Nonproliferative Diabetic Retinopathy.
What happened to similar drugs?
1 of 2 similar drugs in Nonproliferative Diabetic Retinopathy were approved
Approved (1) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
12
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05383209 | Phase 2 | Completed |
| NCT04747197 | Phase 1 | Completed |
Competing Products
3 competing products in Nonproliferative Diabetic Retinopathy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Lucentis | Novartis | Approved | 43 |
| Intravitreal aflibercept injection [IAI] + Sham | Regeneron Pharmaceuticals | Phase 3 | 40 |
| AKB-9778 + Placebo | EyePoint Pharmaceuticals | Phase 2 | 29 |